Paloma Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-8,500
| Closed | -$2.84M | – | 363 |
|
|
2024
Q3 | $2.84M | Buy |
8,500
+6,614
| +351% | +$2.1M | 0.08% | 222 |
|
|
2024
Q2 | $515K | Buy |
+1,886
| New | +$549K | 0.01% | 743 |
|
|
2022
Q3 | – | Sell |
-650
| Closed | -$322K | – | 1024 |
|
|
2022
Q2 | $322K | Sell |
650
-2,437
| -79% | -$1.27M | 0.01% | 739 |
|
|
2022
Q1 | $1.74M | Buy |
3,087
+1,685
| +120% | +$1.02M | 0.05% | 277 |
|
|
2021
Q4 | $1.06M | Buy |
+1,402
| New | +$1.05M | 0.02% | 693 |
|
|
2021
Q3 | – | Sell |
-1,403
| Closed | -$903K | – | 1123 |
|
|
2021
Q2 | $903K | Buy |
1,403
+41
| +3% | +$25K | 0.02% | 681 |
|
|
2021
Q1 | $778K | Sell |
1,362
-396
| -23% | -$235K | 0.02% | 836 |
|
|
2020
Q4 | $1.02M | Buy |
1,758
+1,168
| +198% | +$665K | 0.03% | 566 |
|
|
2020
Q3 | $304K | Sell |
590
-10,985
| -95% | -$5.56M | 0.01% | 1472 |
|
|
2020
Q2 | $5.23M | Buy |
+11,575
| New | +$5.11M | 0.09% | 279 |
|
|
2020
Q1 | – | Sell |
-1,297
| Closed | -$480K | – | 1288 |
|
|
2019
Q4 | $480K | Buy |
1,297
+333
| +35% | +$117K | 0.01% | 1421 |
|
|
2019
Q3 | $321K | Sell |
964
-1,144
| -54% | -$373K | 0.01% | 1481 |
|
|
2019
Q2 | $659K | Buy |
2,108
+663
| +46% | +$199K | 0.01% | 890 |
|
|
2019
Q1 | $442K | Buy |
+1,445
| New | +$390K | 0.01% | 1133 |
|
|
2018
Q4 | – | Sell |
-2,306
| Closed | -$722K | – | 1291 |
|
|
2018
Q3 | $722K | Sell |
2,306
-6,774
| -75% | -$2.1M | 0.01% | 878 |
|
|
2018
Q2 | $2.62M | Buy |
9,080
+6,358
| +234% | +$1.76M | 0.05% | 346 |
|
|
2018
Q1 | $681K | Buy |
+2,722
| New | +$693K | 0.01% | 1197 |
|
|
2017
Q4 | – | Sell |
-3,358
| Closed | -$746K | – | 1887 |
|
|
2017
Q3 | $746K | Sell |
3,358
-5,397
| -62% | -$1.21M | 0.01% | 1314 |
|
|
2017
Q2 | $1.98M | Buy |
8,755
+1,495
| +21% | +$326K | 0.02% | 768 |
|
|
2017
Q1 | $1.45M | Buy |
+7,260
| New | +$1.4M | 0.02% | 1003 |
|
|
2016
Q2 | – | Sell |
-6,801
| Closed | -$930K | – | 2155 |
|
|
2016
Q1 | $930K | Buy |
+6,801
| New | +$893K | 0.02% | 914 |
|
|
2015
Q4 | – | Sell |
-10,000
| Closed | -$1.34M | – | 1707 |
|
|
2015
Q3 | $1.34M | Buy |
10,000
+371
| +4% | +$53.4K | 0.03% | 500 |
|
|
2015
Q2 | $1.45M | Buy |
9,629
+5,830
| +153% | +$834K | 0.03% | 575 |
|
|
2015
Q1 | $514K | Sell |
3,799
-5,755
| -60% | -$713K | 0.01% | 766 |
|
|
2014
Q4 | $1.15M | Buy |
+9,554
| New | +$1.1M | 0.05% | 392 |
|
|
2014
Q3 | – | Sell |
-2,243
| Closed | -$269K | – | 1016 |
|
|
2014
Q2 | $269K | Buy |
+2,243
| New | +$274K | 0.01% | 841 |
|
|
2014
Q1 | – | Sell |
-6,259
| Closed | -$773K | – | 696 |
|
|
2013
Q4 | $773K | Buy |
+6,259
| New | +$763K | 0.04% | 468 |
|
Other funds holding BIO
VAM
AI
Paloma Partners's BIO Position: Q4 2024 in Review
Paloma Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2024, closing a stake of 8,500 shares — an estimated $2.84M sold.
Paloma Partners first reported a position in BIO in Q4 2013 and held it in 27 quarters. The position peaked at $5.23M in Q2 2020. 457 funds tracked by Wall St. Rank hold BIO as of Q4 2024.
- Paloma Partners reported no remaining Bio-Rad Laboratories Class A position as of Q4 2024 after selling out during the quarter.
- Paloma Partners sold 8,500 Bio-Rad Laboratories Class A shares in Q4 2024, an estimated $2.84M.
- Paloma Partners first reported a position in Bio-Rad Laboratories Class A in Q4 2013 and held it in 27 quarters.
- Paloma Partners's Bio-Rad Laboratories Class A position peaked at $5.23M in Q2 2020.
- 457 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2024.
Based on Paloma Partners's 13F filing for Q4 2024, filed 14 Feb 2025.